TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01167140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch II
Description: Percutaneous treatment with the device
Study: NCT01412567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine+HBIG
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine+Placebo
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
Study: NCT04758559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myfood24
Description: An app to support monitoring of food and nutrient intake using robust validated methodology.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Patients will receive standard advice as provided by the clinical team, this may or may not include nutrition.
Study: NCT01669863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO
Description: Use of veno-venous ECMO in non-intubated patients with ARDS
Study: NCT03264066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT01669863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECMO in non-intubated patients
Description: Use of veno-venous ECMO in non-intubated patients with ARDS
Study: NCT04299815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Lactate
Description: 25 grams of D/L lactate dissolved in 300mL water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous sodium lactate
Description: intravenous sodium lactate + oral sodium-chlorid solution
Study: NCT00603473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Orally administered gabapentin
Study: NCT02691884

Intervention type: PROCEDURE
Intervention: maternal abdominal pressure
Description: The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
Study: NCT04121949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADScor®System
Description: The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
Study: NCT03152474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solumedrol 20mg
Description: Dosed Intravenous every 8 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solumedrol 20mg
Description: Dosed Intravenous every 8 hrs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A 100,000 IU
Description: Dosed Intramuscular once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A 100,000 IU
Description: Dosed Intramuscular once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
Study: NCT00975078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenal insufficiency testing
Description: On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 0.5mg/kg body-weight prednisone each morning for 14 days
Study: NCT04689035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVLX-144
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04367181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuse Correlation Spectroscopy (DCS)
Description: Diffuse correlation spectroscopy uses light in the near infrared spectral region to quantify non-invasively cerebral blood flow. The DCS device will be use to monitor blood flow changes over time in all ELGA enrolled babies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplitude Integrated Electroencephalography (aEEG)
Description: Amplitude Integrated Electroencephalography like EEG it is used clinically to monitor brain function in intensive care settings over longer periods of time. aEEG data will be correlated with CBF variation over time
Study: NCT04533737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
Study: NCT06012877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Friendly Program
Description: The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021).
Study: NCT04533737

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
Study: NCT02070289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, 2.5 mg BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, BID or titration, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Tablets, to be decided dose, BID or titration, 14 days
Study: NCT02127892

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: unrelated BM with T cell depletion
Description: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: unrelated cord blood
Description: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: haplo BM with T cell depletion
Description: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
Study: NCT02127892

Intervention type: DEVICE
Group type: OTHER
Intervention: unrelated PBSC with T cell depletion
Description: peripheral blood stem cell will be processed for CD34+ cell isolation.
Study: NCT01356121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
Study: NCT02286297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGRATH® MAC
Description: video-laryngoscopy-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGRATH® MAC
Description: video-laryngoscopy-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: video-laryngoscopy-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: video-laryngoscopy-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: video-laryngoscopy-3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: video-laryngoscopy-3
Study: NCT00515970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm.
Study: NCT03264066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT00515970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep excision
Description: 12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
Study: NCT03264066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Cohort 7
Description: Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
Study: NCT03166306

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET-CT Imaging with [89Zr]-bevacizumab
Description: Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT Imaging with [89Zr]-bevacizumab
Description: Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT Imaging with [89Zr]-bevacizumab
Description: Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
Study: NCT02383537

Intervention type: OTHER
Intervention: Diabetes
Description: the trial is observational with no intervention
Study: NCT03723928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care disease monitoring
Description: Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum Tumor Marker directed disease monitoring
Description: Serum tumor markers every 4-8 weeks without imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaire Administration
Description: Ancillary studies
Study: NCT02611245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
Study: NCT02317094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted training
Description: The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.

Intervention type: DRUG
Group type: OTHER
Intervention: Care as usual
Description: The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
Study: NCT01572831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCT and clinical algorithm for stopping abx
Description: In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and \>4,000).
Study: NCT00515970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shave excision
Description: Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining.
Study: NCT02286297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy
Study: NCT01444664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Clipping of Aneurysm
Description: Surgical clipping of intracranial aneurysm
Study: NCT03939702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986177
Description: An orally administered anticoagulant to prevent and treat thromboembolic events

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986177
Description: An orally administered anticoagulant to prevent and treat thromboembolic events
Study: NCT03815500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Education
Description: Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
Study: NCT00486746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity and dietary counseling)
Description: One-year intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General information on healthy lifestyle habits
Description: A single session
Study: NCT02972970

Intervention type: DEVICE
Group type: OTHER
Intervention: Aveera
Description: Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
Study: NCT00884793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study NNRTI
Description: Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study PI
Description: Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
Study: NCT01372618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 / Pasireotide
Description: SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
Study: NCT02061384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Accutane is used for the treatment of severe acne

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Accutane is used for the treatment of severe acne

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol is a form of vitamin D given twice daily (BID)
Study: NCT01264302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride Tablets 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride Tablets 5 mg